This excerpt taken from the NVS 6-K filed Apr 16, 2008.
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
· Phase II study extension shows 68-73% of patients with multiple sclerosis remained relapse-free after three years of treatment with oral FTY720(1)
· New data demonstrate 89% of patients free from active brain lesions the injury caused by MS three years after starting treatment(1)
· MS, a devastating disease causing progressive disability, affects 2.5 million people worldwide including many young adults(2)
· FTY720 regulatory filings planned before end of 2009 in US and EU